Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Roger Belizaire, MD, PhD


Pathology

No Ratings Available - Why Not? Make an Appointment

Roger Belizaire, MD, PhD

Physician

  • Assistant Professor of Pathology, Dana-Farber Cancer Institute and Harvard Medical School
  • Associate Pathologist, Division of Transfusion Medicine, Brigham and Women’s Hospital

Clinical Interests

  • Transfusion Medicine

Contact Information

  • Office Phone Number857-215-1563
  • Fax617-582-8761

Bio

Dr. Belizaire graduated from Washington University School of Medicine in 2012 and received his training in Clinical Pathology and Transfusion Medicine at Brigham and Women's Hospital and Harvard Medical School. He is an Assistant Professor of Pathology at Harvard Medical School with appointments at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital. He is an Associate Medical Director in the Division of Transfusion Medicine at the Brigham and Women’s Hospital. His research focuses on oncogenic signaling and targeted therapies in myeloid malignancies.

Board Certification:

  • Clinical Pathology

Fellowship:

  • Harvard Medical School

Residency:

  • Brigham and Women's Hospital

Medical School:

  • Washington University School of Medicine

Research

The Belizaire Lab studies oncogenic signaling in myeloid neoplasms, including myelodysplastic syndromes, chronic myelomonocytic leukemia, and juvenile myelomonocytic leukemia. We use a combination of proteomics, functional genomics, and in vivo models to understand mechanisms of oncogenesis and identify new targeted therapies for patients with myeloid neoplasms. 

A STUB1 ubiquitin ligase/CHIC2 protein complex negatively regulates the IL-3, IL-5, and GM-CSF cytokine receptor common ß chain (CSF2RB) protein stability. J Biol Chem. 2022 10; 298(10):102484.
View in: PubMed

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Adv. 2022 05 10; 6(9):2835-2846.
View in: PubMed

Clonal Hematopoiesis and CKD Progression. J Am Soc Nephrol. 2022 05; 33(5):878-879.
View in: PubMed

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Blood. 2021 04 22; 137(16):2209-2220.
View in: PubMed

Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion. Transfus Med Rev. 2020 10; 34(4):242-249.
View in: PubMed

Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens. Transfusion. 2019 07; 59(7):2256-2263.
View in: PubMed

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
View in: PubMed

Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017 10 05; 21(4):547-555.e8.
View in: PubMed

Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. Transfusion. 2015 Sep; 55(9):2142-8.
View in: PubMed

Salt Accelerates Allograft Rejection through Serum- and Glucocorticoid-Regulated Kinase-1-Dependent Inhibition of Regulatory T Cells. J Am Soc Nephrol. 2015 Oct; 26(10):2341-7.
View in: PubMed

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014 Sep; 32(9):941-6.
View in: PubMed

CD8a(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity. 2011 Aug 26; 35(2):236-48.
View in: PubMed

Spontaneous inactivating p53 mutations and the "selfish cell". Aging (Albany NY). 2011 Mar; 3(3):181.
View in: PubMed

ITAM signaling in dendritic cells controls T helper cell priming by regulating MHC class II recycling. Blood. 2010 Oct 28; 116(17):3208-18.
View in: PubMed

Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A. 2009 Oct 13; 106(41):17463-8.
View in: PubMed

SV2B regulates synaptotagmin 1 by direct interaction. J Biol Chem. 2004 Dec 10; 279(50):52124-31.
View in: PubMed

Characterization of synaptogyrin 3 as a new synaptic vesicle protein. J Comp Neurol. 2004 Mar 08; 470(3):266-81.
View in: PubMed

Differential distribution and developmental expression of synaptic vesicle protein 2 isoforms in the mouse retina. J Comp Neurol. 2003 May 19; 460(1):106-22.
View in: PubMed

Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003 Jan; 179(1):38-46.
View in: PubMed

Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain. Exp Neurol. 2002 Oct; 177(2):376-84.
View in: PubMed

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 2002 Aug 07; 13(11):1437-41.
View in: PubMed

Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett. 2002 Jul 05; 326(3):155-8.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Jimmy Fund Building 215C
Boston, MA 02215
Get Directions

Top